Patent intelligence · US
US 9114138
1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
Patent details — US 9114138
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 25, 2015
- Expiration
- Aug 20, 2035
- Applicant
- Addex Pharma, S.A.
- Claims
- 11
- CPC classes
- A61K, A61K31/444, A61K31/4545, A61K31/5377
Quick answer
US 9114138 (1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones) is held by Addex Pharma, S.A.. Status: granted. Granted Aug 25, 2015. Expires Aug 20, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Addex Pharma, S.A.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K31/444, A61K31/4545, A61K31/5377, A61K45/06, A61K47/10
More from Addex Pharma, S.A.
Related pharmaceutical patents in our USPTO index.
-
US 11071729
1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
granted -
US 10071095
1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of neurological and psychiatric disorders
granted -
US 9938270
Mono-phosphate salt of 6-fluoro-2-[4-(pyridin-2-yl)but-3-yn-1-yl]imidazo[1,2A]pyridine (dipraglurant) and polymorphs thereof as negative allosteric modulator of MGLU5 receptor
granted -
US 9765091
Tetrahydropyrazolo [3,4-b] azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors
granted -
US 9737533
1,2,4-triazolo [4,3-A] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
granted -
US 9266834
1, 4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of MGLUR2-receptors
granted -
US 9226930
1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and psychiatric disorders
granted -
US 9132122
1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′]bipyridinyl-2′-ones
granted
Frequently asked questions
What is US patent 9114138?
US 9114138 (1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones) is held by Addex Pharma, S.A.. Status: granted. Granted Aug 25, 2015. Expires Aug 20, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9114138?
Addex Pharma, S.A. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 40 pharmaceutical patents for this assignee.
When does US 9114138 expire?
Our index shows an expiration date of Aug 20, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.